Mycophenolate mofetil (MMF) is an alternative immunosuppressant which inhibits the proliferation of T and B lymphocytes. The purpose of the present study was to evaluate the safety and efficacy of MMF as salvage therapy for chronic GVHD (cGVHD) in children receiving allogeneic bone marrow transplantation. Fifteen children, 3-16 years of age, who had received grafts from HLA-compatible siblings (n ‫؍‬ 8), partially matched related donors (n ‫؍‬ 2) or matched unrelated donors (n ‫؍‬ 5), developed extensive cGVHD which had proved unresponsive to standard immunosuppressive therapy. Patients were treated with MMF at the dose of 15-40 mg/kg/day in combination with other immunosuppressive therapy for a median of 4 months (range 1-15 months). The overall response rate (complete or partial response) was 60%. Thirteen percent had only minor responses, whereas 27% of patients had progressive disease. Best responses were seen in patients with GI tract (60% of complete responses) or mouth (33% of complete responses) cGVHD and skin involvement (43% of complete responses) that did not include sclerodermatous manifestations. Once MMF was started, improvements in the clinical manifestations of cGVHD allowed a significant reduction of steroids in 45% of patients and discontinuation in 27% of cases. Six patients (40%) experienced adverse events, with gastrointestinal symptoms predominating. Five patients experienced opportunistic infections. MMF was discontinued after 35-180 days in six patients for the following reasons: parents choice (n ‫؍‬ 2), liver toxicity (n ‫؍‬ 1), poor compliance (n ‫؍‬ 2), and no response (n ‫؍‬ 1). In conclusion, these preliminary results suggest that MMF in combination with other immunosuppressive agents may have a role to play in patients with cGVHD. Prospective clinical trials are needed to establish exact indications for therapy and dosage scheduling. Bone Marrow Transplantation (2000) 25, 1067-1071.
Despite improvements in post-transplant immunosuppression 20% to 40% of long-term survivors of HLA-identical marrow grafts and up to 70% of patients receiving marrow from unrelated donors still experience significant chronic graft-versus-host disease (cGVHD). 1 Fewer children than adults develop cGVHD. 2 Nevertheless, the treatment of this severe complication remains one of the great challenges in allogeneic bone marrow transplantation (BMT).
Cyclosporine (CsA) and steroids have been shown to be effective in the treatment of established cGVHD. However, therapeutic options are limited for patients who are resistant to first-line therapy. 3, 4 Mycophenolate mofetil (MMF) is a powerful immunosuppressant that inhibits the proliferation of T and B lymphocytes. Since its introduction, MMF has rapidly gained acceptance among organ transplant physicians, whereas there is a paucity of data regarding its use in the treatment of GVHD after BMT. [5] [6] [7] The aim of the present study was to evaluate the safety and efficacy of MMF as therapy for resistant cGVHD in children receiving allogeneic BMT.
Patients and methods
Between April 1992 and January 1999 15 children (10 males and five females) aged 3-16 years (median 7 years), developed cGVHD after receiving HLA-matched sibling marrow (n ϭ 7), sibling peripheral blood progenitor cells (n ϭ 1), partially matched relative marrow (n ϭ 2) or matched unrelated marrow grafts (n ϭ 5). The transplants were performed for a variety of hematological malignancies: acute lymphoblastic leukemia (n ϭ 8), acute myeloid leukemia (n ϭ 2) and chronic myelomonocytic leukemia (n ϭ 2). Three patients received the transplant for genetic disease (Fanconi anemia, n ϭ 1; familial hemophagocytic lymphohistiocytosis, n ϭ 1; adrenoleukodystrophy, n ϭ 1).
Ten transplants were performed using total body irradiation as part of the preparative regimen. In patients transplanted from a family donor, GVHD prophylaxis mainly consisted of CsA alone (n ϭ 7) or the combination of CsA and methotrexate (MTX) (n ϭ 2) or CsA and antithymocyte globulin (ATG) (n ϭ 1). In the five patients given an unrelated marrow donor transplant the GVHD prophylaxis was CsA and short-course MTX combined with ATG (n ϭ 3) or Campath (n ϭ 2). The diagnosis of cGVHD was made according to standard clinical criteria.
All patients had extensive cGVHD, 13 of the 15 patients were also classified as having high-risk cGVHD due to either thrombocytopenia, progressive disease, or combined skin and liver cGVHD.
Patients were eligible if they had progressive disease which had proved unresponsive to standard immunosuppressive therapy, including at least a steroid and CsA. Informed consent according to the institutional guidelines was obtained for each patient enrolled.
A complete organ response (CR) of cGVHD was classified as complete disappearance of skin, joint, oral mucosa, liver, gastrointestinal (GI) tract, lung or ocular clinical manifestations. Partial responses (PR) were defined as a greater than 50% response in organ involvement, but less than a CR. Minor responses (MR) were defined as Ͻ50% response in organ involvement. No response (NR) referred to progressive worsening of cGVHD.
The difference between groups was compared using Student's t-test.
Results
All patients successfully engrafted. Acute GVHD was scored as grade 0 in two patients, grade 1 in three, grade 2 in three, grade 3 in six and grade 4 in one.
The clinical characteristics of cGVHD are detailed in Table 1 . Extensive cGVHD with involvement of skin (n ϭ 14), oral mucosa (n ϭ 6), liver (n ϭ 6), GI tract (n ϭ 5), lungs (n ϭ 1), and eyes (n ϭ 1) developed 90-610 days (median 110 days) after transplant. Three patients were thrombocytopenic. All patients had failed prior immunosuppressive therapy including CsA (n ϭ 15), steroids (n ϭ 15), photopheresis (n ϭ 5), thalidomide (n ϭ 4), azathioprine (n ϭ 4), MTX (n ϭ 2) or FK506 (n ϭ 1). Furthermore, five of these patients could no longer receive CsA or FK506 due to severe complications occurring with the administration of these drugs. cGVHD was progressive in 11 (74%), quiescent in two (13%) and de novo in two (13%) cases.
Patients were treated with MMF at the dose of 15-40 mg/kg/day (1-2 g/day) in addition to CsA and steroids (n ϭ 8), CsA (n ϭ 3), steroids-photopheresis Ϯ CsA (n ϭ 2), CsA-steroids and PUVA (psoralen and ultraviolet-A irradiation) (n ϭ 1), or azathioprine (n ϭ 1). The median time to start MMF treatment was 22 months (range 4-79 months) after BMT. The time from the onset of cGVHD to the initiation of MMF treatment ranged between 18 and 2271 days (median 242 days). The duration of therapy has ranged from 1 month to 15 months (median 4 months), with 10 patients continuing to receive MMF at the time that these data were compiled.
Clinical response to MMF treatment is summarized in Table 1 . Overall, nine patients (60%) had a sustained response: two patients (13%) had a CR of all clinical manifestations of cGVHD, five (33%) had combined CR and PR in different organ involvement and two (13%) patients had a PR. Two patients (13%) had only minor responses and four (27%) had progressive disease (including two patients with multiple organ involvement who had CR of a single organ but progressed in the others).
Six (43%) of the 14 patients with chronic cutaneous GVHD achieved a clinical CR; seven patients had the sclerodermatous form of the disease, one of these showed a CR including softening of the skin, increased range of motion and improved performance status. Two (33%) of the six patients with oral involvement had a CR. One (17%) of the six patients with liver involvement showed a CR. Three (60%) of the five patients with GI tract involvement experienced a CR. Three patients with thrombocytopenia had normalization of peripheral blood platelet counts during MMF therapy. A PR was seen only in one of three patients with joint contractures. None of the patients with ocular symptoms (one case) and lung involvement (one case) responded.
During MMF treatment, steroid therapy could be discontinued in three of the 11 patients who initially remained on steroids in addition to MMF. Five patients showed a significant reduction in steroid requirement. The median dose of steroids (expressed as mg of prednisone/kg of patient body weight) at the time of inclusion and at the end of treatment (or last observation as appropriate) was 0.6 mg/day and 0.2 mg/day respectively (P ϭ 0.01), corresponding to a percentage of steroid reduction ranging between 50% and 83% (Table 1 ). In three cases the dose of steroids did not change during the course of treatment with MMF.
MMF was discontinued after 35-180 days in six patients for the following reasons: parents choice (n ϭ 2), liver toxicity (n ϭ 1), poor compliance (nausea and vomiting, n ϭ 1; patient unable to swallow, n ϭ 1), and no response (n ϭ 1). In one patient MMF was re-instituted successfully.
Adverse gastrointestinal events including diarrhea, nausea and vomiting were observed in five patients receiving MMF. One patient developed severe liver toxicity. None of the patients had evidence of hematological toxicity. Five patients experienced opportunistic infections including candida (n ϭ 3), herpes simplex (n ϭ 1) and CMV infection (n ϭ 1).
Monitoring of the phenotypic regeneration of peripheral blood mononuclear cells showed no significant differences between the numbers of lymphocytes, CD3 ϩ , CD4 ϩ , CD8 ϩ , CD19 ϩ and CD56 ϩ cells before MMF therapy and at the end of treatment or last observation as appropriate (data available for 11/15 patients). The median values of lymphocytes ϫ 10 All patients are currently alive, 11 have cGVHD requiring immunosuppressive therapy. As of June 1999, three patients have Karnofsky performance scores у90%, 10 between 70% and 89% and two patients have Karnofsky performance scores р50%. 
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Discussion
MMF is a novel immunosuppressive agent that showed promise in preventing the rejection of organ allografts.
9,10
Orally administered MMF is hydrolyzed by esterases to mycophenolic acid, its biologically active component.
11
This reversibly inhibits eukaryotic inosine monophophate dehydroxygenase, blocking the de novo synthesis of the purine guanosine, the effect of which is selective depletion of guanine nucleotide pools. As purine synthesis in lymphocytes depends primarily on the de novo pathway, by this depletion both T and B lymphocytes are arrested in the S phase of the cell cycle. The result is a reduction in the generation of effector lymphocytes for T cell-mediated functions and for antibody production. 12 Studies in animal models as well as preliminary clinical trials have indicated that MMF might be an effective agent for prophylaxis of acute GVHD after allogeneic BMT. [13] [14] [15] [16] In contrast, only little data exist on the use of MMF in the treatment of established cGVHD. [5] [6] [7] Even though the data we present here are restricted to a small number of patients with a relatively short follow-up, some notable observations can be made.
MMF therapy is a new potentially beneficial treatment for some patients failing prolonged treatment with multimodality immunosuppressive therapy. In our series 60% of children obtained a sustained response (CR and/or PR), with two cases attaining the complete disappearance of all clinical manifestations of cGVHD. All these patients except for one had high-risk cGVHD defined by the presence of clinically extensive disease failing primary treatment, progressive-type onset, combined skin and liver cGVHD (one case) and persisting thrombocytopenia (one case). It is worth recalling that all the sustained responses were obtained with MMF in association with other immunosuppressive agents (CsA and steroids in the majority of patients) and therefore it may be difficult to discern whether the improvements observed in our series depend on MMF itself or the combination of drugs. In this respect, it should be pointed out that a synergism between MMF and CsA in preventing GHVD has already been described in an animal model. 13 Best responses were seen in patients with GI tract (60% of CR) or mouth (33% of CR) cGVHD and skin involvement (43% of CR) that did not include sclerodermatous manifestations. Interestingly, patients with concomitant thrombocytopenia had normalization of peripheral blood platelet counts.
In our study at the initiation of MMF, 11 of 15 patients were receiving steroids. Once MMF was initiated, gradual improvements of clinical manifestations of cGVHD allowed a timely reduction of steroids in five cases (45%) and discontinuation in three cases (27%). Of note, the percentage of steroid reduction was у50% in all cases.
Optimal MMF dosing schedules for the treatment of GVHD remain to be defined. In adult patients receiving allogeneic BMT, the levels of mycophenolic acid are below the trough blood levels measured after solid organ transplantation. 15 It has been suggested that BMT recipients who experience GVHD of the GI tract might have subtherapeutic levels of the active metabolite. 15 We have no data to support this hypothesis since pharmacokinetic studies have not been performed in our series. However, three of the five patients with intestinal GVHD achieved a CR. Nevertheless, it will be important to define an appropriate regimen in pediatric patients undergoing BMT which may enable the dose to be tailored to individual needs and hence improve both efficacy and tolerability of MMF in clinical practice.
In this respect, it should be noted that in the current study six patients (40%) experienced adverse events. Diarrhea, nausea and vomiting were the most common clinically relevant adverse reactions, occurring in one third of patients. The frequency of gastrointestinal side-effects in our study was higher than the data already reported, 5,7 although we cannot exclude that the concomitant administration of several medications might be relevant to this point. Nevertheless, the overall frequency of adverse reactions seems to be similar to the data reported in other studies, 7 and it should be emphasized that MMF treatment was discontinued because of complications in two patients only. One patient was taken off treatment because of severe liver toxicity. However, the presence of cGVHD with liver involvement might in turn have predisposed to liver abnormalities. In this patient, hepatic dysfunction persisted after MMF discontinuation and histologic evaluation revealed characteristic bile duct abnormalities and portal inflammation. To our knowledge, severe liver toxicity related to MMF has been reported in one study only. 5 The other events leading to discontinuation of the drug were nausea and vomiting. The doses used did not appear to correlate with adverse events, however a dose-escalation study is warranted to address this issue.
It has been argued that MMF may increase the risk for opportunistic infections, particularly CMV disease. 17 However, none of the patients included in our series experienced leukopenia, and immunological recovery did not seem to be adversely affected by the use of MMF, thereby resulting in a frequency of opportunistic infections similar to that reported in the literature.
